Erste Asset Management GmbH Sells 4,665 Shares of IDEXX Laboratories, Inc. $IDXX

Erste Asset Management GmbH reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 32.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,757 shares of the company’s stock after selling 4,665 shares during the quarter. Erste Asset Management GmbH’s holdings in IDEXX Laboratories were worth $6,152,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Empowered Funds LLC raised its stake in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares during the period. Sivia Capital Partners LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth approximately $265,000. AlphaQuest LLC increased its holdings in IDEXX Laboratories by 7.3% in the 2nd quarter. AlphaQuest LLC now owns 398 shares of the company’s stock worth $213,000 after acquiring an additional 27 shares in the last quarter. Brighton Jones LLC bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $351,000. Finally, World Investment Advisors purchased a new position in IDEXX Laboratories during the second quarter valued at approximately $456,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 0.6%

Shares of IDXX stock opened at $656.73 on Friday. The company’s fifty day simple moving average is $672.95 and its two-hundred day simple moving average is $668.97. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The stock has a market cap of $52.29 billion, a P/E ratio of 50.25, a PEG ratio of 4.01 and a beta of 1.67. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the subject of a number of analyst reports. UBS Group reduced their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Piper Sandler dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Morgan Stanley increased their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Finally, Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $783.33.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the sale, the director directly owned 648 shares of the company’s stock, valued at $407,345.76. This represents a 69.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nimrata Hunt sold 2,693 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the transaction, the executive vice president directly owned 19,899 shares of the company’s stock, valued at approximately $13,163,984.46. This trade represents a 11.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 20,873 shares of company stock worth $13,408,523. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.